GB Discovery & Functional Biology Platform
GB uses functional metabolomics to measure gut microbial ecosystem activity and host-microbe biology,
potentially supporting biomarkers, patient stratification, partnerships, longitudinal data, and discovery.
CS-0003: First-in-Class Mucosal-Immune Modulator
Our lead therapeutic is designed to stabilize the GI mucosal barrier, suppress stress-induced bacterial
virulence signaling, and support balanced mucosal-immune responses.
Lead indication: Prevention of GI Surgical Site Infection in High-Risk GI Surgery
Advancing a New Approach to GI Disease
32 Biosciences is developing therapies designed to act earlier in GI disease biology, before infection or
inflammatory amplification.
– Physicians’ Hippocratic Oath
